alexa
Reach Us +44-1647-403003
The Androgen Receptor in Castration-Resistant Prostate Cancer: Still a Clinical Opportunity? | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Editorial

The Androgen Receptor in Castration-Resistant Prostate Cancer: Still a Clinical Opportunity?

Richard D. Finkelman1* and Glen Clack2

1Senior Medical Director, Clinical Research, Oncology, AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, USA

2Medical Science Director, Global Medicines Development, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK

*Corresponding Author:
Richard D. Finkelman
AstraZeneca Pharmaceuticals LP
1800 Concord Pike, P.O. Box 15437
Wilmington, DE 19850-5437, USA
Tel: 302-886-1685
Fax: 302-886-2622
E-mail: [email protected]

Received Date: January 13, 2012; Accepted Date: January 29, 2012; Published Date: February 01, 2012

Citation: Finkelman RD, Clack G (2012) The Androgen Receptor in Castration- Resistant Prostate Cancer: Still a Clinical Opportunity? J Cancer Sci Ther S5:e001. doi:10.4172/1948-5956.S5-e001

Copyright: © 2012 Finkelman RD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Share This Page
Top